Efficacy of vaccination at 4 and 6 weeks in the control of canine parvovirus.
Seroconversion after early vaccination at four weeks against canine parvovirus (CPV) using a high antigen titre vaccine was evaluated in 121 puppies from three breeds of dogs housed in kennels representative of the private practitioner's environment. The trial included 52 German shepherd pups, 25 Rottweiler pups and 44 Boerboel pups. From each group 11, 4, and 18 puppies acted as control dogs, respectively. Depending on the different groups, puppies were vaccinated at 4, 6, 9 and 12 weeks. The experimental group differed from the control group in that they received the high titre vaccine at 4 weeks of age, whereas the control group was not vaccinated at 4 weeks. Blood was collected from all pups prior to vaccination to measure maternally derived colostral antibody. The results indicated that vaccination at 4 weeks of age in pups with high maternally derived antibody levels, results in seroconversion rates that may lead to a reduction in the window of susceptibility with respect to CPV infection. The implications of the findings with respect to dogs in heavily contaminated environments are discussed.
Rant en Dal Animal Hospital, Mogale City, South Africa. kdcramer@mweb.co.za
K G M
KG
De Cramer
E
E
Stylianides
M
M
van Vuuren
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D004283:Dog Diseases / Q000276:immunology / Q000517:prevention & control*; D004285:Dogs; D007112:Immunity, Maternally-Acquired / Q000276:immunology; D010322:Parvoviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D017993:Parvovirus, Canine / Q000276:immunology*; D014611:Vaccination / Q000662:veterinary; D014613:Vaccines, Attenuated / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines